8-KMaterial AgreementsOther EventsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Material Agreement (Feb 2, 2016)

Filed February 2, 2016For Securities:ABT

Summary

Abbott Laboratories (ABT) announced on February 1, 2016, its entry into a definitive Agreement and Plan of Merger with Alere Inc. The agreement outlines the acquisition of Alere by Abbott through a merger, where Alere will become a wholly owned subsidiary of Abbott. This transaction is structured as an all-cash deal, with Alere shareholders set to receive $56.00 per share. The acquisition is a significant strategic move for Abbott, likely aimed at expanding its diagnostics business. Completion of the merger is contingent upon customary closing conditions, including Alere shareholder approval, regulatory approvals such as Hart-Scott-Rodino, and other antitrust clearances. Investors should note that while the agreement is definitive, there is no guarantee of completion or the realization of expected benefits. The filing also includes standard cautionary statements regarding forward-looking statements and potential risks associated with the transaction.

Key Highlights

  • 1Abbott Laboratories has entered into a definitive agreement to acquire Alere Inc.
  • 2The acquisition will be an all-cash transaction valued at $56.00 per share of Alere common stock.
  • 3Alere will become a wholly owned subsidiary of Abbott upon successful completion of the merger.
  • 4The transaction is subject to customary closing conditions, including Alere shareholder approval and regulatory clearances (e.g., HSR Act).
  • 5The merger agreement contains representations and warranties customary for transactions of this nature.
  • 6Abbott cautions that there is no guarantee the acquisition will be completed or that expected benefits will be realized.
  • 7The filing is primarily focused on the announcement of this material definitive agreement.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report Abbott Laboratories' entry into a material definitive agreement, specifically the Agreement and Plan of Merger with Alere Inc., announcing its intent to acquire Alere.

Abbott has agreed to acquire Alere for $56.00 in cash per share of Alere common stock.

Key conditions include the adoption of the merger agreement by Alere shareholders, absence of any prohibitory judgments or laws, expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and receipt of other required antitrust approvals. Both parties must also meet certain conditions regarding the accuracy of their representations and warranties and the performance of their obligations.

Yes, Abbott cautions that there is no guarantee that the acquisition of Alere will be completed or when it will be completed, nor that the expected benefits of the acquisition will be realized. Risks and uncertainties that may cause actual results to differ materially are also mentioned, with further details referenced in Abbott's Form 10-K.